Patents Examined by Lisa V. Cook
  • Patent number: 12292449
    Abstract: A detection device and associated systems and methods for detecting analytes from a multiplex reaction are described. In particular, a device for conducting at least one detection reaction using a modified ELISA method including a surface with a detection region and a reference region, a detection sensor, and a light source. The detection device may include a complementary metal-oxide-semiconductor (CMOS) image sensor. The device may be used to measure and report discrete quantities or combinations of discrete analytes, providing information to aid in the prognosis and/or diagnosis of altered states of health in vertebrates.
    Type: Grant
    Filed: September 26, 2023
    Date of Patent: May 6, 2025
    Assignee: Xcellcure, LLC
    Inventors: Leah Amir, Gary Anderson
  • Patent number: 12287335
    Abstract: Herein is reported a method for determining the binding affinity of the binding sites of a bivalent full length antibody of the human IgG1 subclass to a homo-multimeric antigen comprising the steps of i) incubating a mixture comprising the antibody and a polypeptide that is derived from lysine-gingipain of Porphyromonas gingivalis at a pH of from pH 7.5 to pH 8.5, in the presence of a reducing agent, at a temperature of from 30° C. to 42° C., for time of from 10 min. to 240 min. to cleave the antibody into Fabs and Fc-region, and ii) determining the binding affinity of the Fabs of the antibody for its antigen using a surface plasmon resonance method by directly applying the incubated reaction mixture obtained in the previous step in the surface plasmon resonance method and therewith determining the binding affinity of the binding sites of the bivalent full length antibody of the human IgG1 subclass.
    Type: Grant
    Filed: October 2, 2020
    Date of Patent: April 29, 2025
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Michael Molhoj, Christian Gassner, Joerg Moelleken, Manuel Endesfelder
  • Patent number: 12286484
    Abstract: Targeting metastasis stem cells through a fatty acid receptor. The disclosure provides the use of blockers or inhibitors of CD36 activity or expression for the treatment of oral squamous cell cancer (OSCC), particularly for the treatment of generated metastases and for diminish is generation from primary tumours. Apart from shRNAs, anti-CD36 antibodies are provided as blockers or inhibitors, especially those that block the binding of CD36 to oxidized LDL and fatty acids and their incorporation into cells, because the promotion of their transport is indicated as the mechanism by which CD36 promote metastases dissemination and growth. Also provided is a method for identifying candidates to anticancer agents, particularly for OSCC metastasis, among those that promote in CD36+ cells, in vivo or in vitro, effects associated to CD36 depletion or blocking such as decrease of growth accumulation of lipid droplets and decrease of size in the case of metastases.
    Type: Grant
    Filed: September 15, 2020
    Date of Patent: April 29, 2025
    Assignees: FUNDACIÓ INSTITUT DE RECERCA BIOMÈDICA (IRB BARCELONA), INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANçATS
    Inventors: Salvador Aznar Benitah, Gloria Pascual Angulo, Andres Castellanos Martin, Merce Martin Peña
  • Patent number: 12282014
    Abstract: The present invention provides methods of screening for compounds that interfere with the interaction between ERG. ETV1, ETV4 or ETV5 and mSWI/SNF (BAF) chromatin remodeling complex proteins. Included are methods of screening for compounds that interfere with the interaction between ERG, ETV1, ETV4 or ETV5 and BAF155. Methods of treating prostate cancer with compounds that interfere with the interaction between ERG, ETV1, ETV4 or ETV5 and mSWI/SNF (BAF) chromatin remodeling complex proteins are also provided.
    Type: Grant
    Filed: November 18, 2016
    Date of Patent: April 22, 2025
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Cigall Kadoch, Gabriel Sandoval, William C. Hahn
  • Patent number: 12282026
    Abstract: The present disclosure relates to a composition for screening an intestinal environment-improving material and a screening method using the composition, and according to the composition and the method of the present disclosure, it is possible to provide an effective analysis method for screening a microbiota-improving candidate material in a personalized manner by providing a method for verifying personalized probiotics, prebiotics, foods, health functional foods and drugs under in vitro conditions based on microbiota and microbiota metabolites.
    Type: Grant
    Filed: December 21, 2021
    Date of Patent: April 22, 2025
    Assignee: HEM PHARMA INC.
    Inventors: Soyoung Park, Yosep Ji
  • Patent number: 12196763
    Abstract: This disclosure provides for compositions and methods that can be used to predict an individual's risk for experiencing a cardiovascular event following a surgical procedure (e.g., a non-cardiac surgical procedure).
    Type: Grant
    Filed: June 13, 2018
    Date of Patent: January 14, 2025
    Assignees: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA, AMERICAN HEART ASSOCIATION, INC
    Inventors: Wade T. Rogers, Jana M. Schmierer, Jonni S. Moore, Emile R. Mohler, III
  • Patent number: 12195537
    Abstract: Provided is an anti-4-1BB antibody or an antigen-binding fragment thereof, and uses thereof.
    Type: Grant
    Filed: December 2, 2019
    Date of Patent: January 14, 2025
    Assignee: ABL BIO, INC.
    Inventors: Eunyoung Park, Yangsoon Lee, Hyejin Chung, Uijung Jung, Youngdon Pak, Jun Hyun Jeong, Yeunju Kim, Seawon Ahn, Byungje Sung
  • Patent number: 12196757
    Abstract: Compositions and methods relating to a panel of antigen biomarkers for the early detection of ovarian cancer. The compositions and methods encompass antigen biomarkers coupled to a substrate, with the biomarkers being selected from the group consisting of one or more of ICAM3, CTAG2, p53, STYXL1, PVR, POMC, NUDT11, TRIM39, UHMK1, KSR1, and NXF3.
    Type: Grant
    Filed: December 28, 2021
    Date of Patent: January 14, 2025
    Assignees: ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY, THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
    Inventors: Benjamin Katchman, Karen Anderson, Garrick Wallstrom, Joshua LaBaer, Daniel Cramer
  • Patent number: 12169167
    Abstract: Disclosed are devices, kits, apparatus, and methods for rapid homogenous cell staining and imaging.
    Type: Grant
    Filed: February 19, 2020
    Date of Patent: December 17, 2024
    Assignee: Essenlix Corporation
    Inventors: Stephen Y. Chou, Wei Ding, Ji Li, Shengjian Cai, Yu Sun
  • Patent number: 12163964
    Abstract: Provided are methods for the detection or quantitation of amyloid beta. In a particular aspect, provided herein are methods for detecting amyloid beta or fragments thereof by mass spectrometry. In another aspect, provided herein are methods for determining the ratio of amyloid beta 42 (A?42) to amyloid beta 40 (A?40). In another aspect, provided herein are methods for diagnosis or prognosis of Alzheimer's disease or dementia.
    Type: Grant
    Filed: June 13, 2022
    Date of Patent: December 10, 2024
    Assignee: QUEST DIAGNOSTIC INVESTMENTS LLC
    Inventors: Diana Tran, Darren Weber, Nigel Clarke
  • Patent number: 12153047
    Abstract: The method according to the invention enables the confirmation of infections/carriage caused by Streptococcus agalactiae bacterial species. The method employs a specific reaction of selected epitopes that are part of immunoreactive proteins of clinical isolates of Streptococcus agalactiae with antibodies present in the serum.
    Type: Grant
    Filed: January 9, 2019
    Date of Patent: November 26, 2024
    Assignees: UNIWERSYTET JAGIELLONSKI, INSTYTUT IMMUNOLOGII I TERAPII DOSWIADCZALNEJ POLSKIEJ AKADEMII NAUK
    Inventors: Monika Brzychczy-Wloch, Anna Dobrut, Sabina Gorska, Ewa Brzozowska, Andrzej Gamian
  • Patent number: 12140594
    Abstract: The present invention relates to a non invasive diagnostic method of pancreatic ductal adenocarcinoma (PDAC) in a subject said method comprising the step of measuring the level of ?ig-h3 protein in a blood sample wherein the serum level of ?ig-h3 is positively correlated with the risk of having a PDAC. By following studies on 2 distinct cohorts of 20 and 104 of PDAC patients, and on PDAC mouse model, the inventors show that ?ig-h3 can be directly detected in the blood sample and ?ig-h3 is expressed very early in tumorigenesis in pancreatic neoplastic lesions. The present invention also relates to antagonist of ?ig-h3 protein, for use in the treatment of PDAC. The inventors found that ?ig-h3 bind directly on CD8+ T cells by reducing their activation and cytotoxic properties. Furthermore, the use of neutralizing ?ig-h3 antibodies in PDAC mouse model, reduced tumor growth by enhancing CD8+ T cell anti-tumoral response.
    Type: Grant
    Filed: July 7, 2023
    Date of Patent: November 12, 2024
    Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE—CNRS, UNIVERSITE CLAUDÉBERNARD—LYON 1, CENTRE LEON BERARD, KIST (KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY)
    Inventors: Kim In-San, Philippe Bertolino, Ana Hennino
  • Patent number: 12128102
    Abstract: The invention relates to COnditional Bispecific Redirected Activation constructs, or COBRAs, that are administered in an active pro-drug format. Upon exposure to tumor proteases, the constructs are cleaved and activated, such that they can bind both tumor target antigens (TTAs) as well as CD3, thus recruiting T cells expressing CD3 to the tumor, resulting in treatment.
    Type: Grant
    Filed: July 21, 2023
    Date of Patent: October 29, 2024
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Patrick Baeuerle, Robert B. DuBridge, Holger Wesche, Luke Evnin, Jeanmarie Guenot, Anand Panchal, Maia Vinogradova
  • Patent number: 12084492
    Abstract: The present disclosure provides anti-amyloid ? (A?) antibodies and antibody fragments that preferentially bind soluble amyloid A? protofibril/oligomer and trigger ADPC in microglial cells, anti-amyloid ? (A?) antibodies and antibody fragments that reduce soluble amyloid A? protofibril/oligomer levels and insoluble amyloid A? plaque in brain tissue, and the use of anti-A? protofibril/oligomer antibodies and antibody fragments in therapy, prophylaxis, diagnosis, screening, and monitoring of conditions associated with A? protein aggregation, in particular Alzheimer's disease (AD).
    Type: Grant
    Filed: January 19, 2024
    Date of Patent: September 10, 2024
    Inventors: Yubin Wang, Lei Huang, Xin Du
  • Patent number: 12077600
    Abstract: The present invention relates to a novel monoclonal antibody that specifically binds to a conformation dependent epitope on human thymidine kinase 1 (hTK-1; SEQ ID NO:1), to methods for quantifying hTK-1 employing the antibody and to the use of the anti-hTK-1 antibody in quantifying hTK-1.
    Type: Grant
    Filed: October 13, 2020
    Date of Patent: September 3, 2024
    Assignee: Roche Diagnostics Operations, Inc.
    Inventors: Hartmut Duefel, Alfred Engel, Frank Kroner, Thomas Meier, Sandra Rutz, Michael Schraeml, Gloria Tabares, Ulrike Kurtkaya, Boris Pinchuk, Christina Zimmermann
  • Patent number: 12064473
    Abstract: Disclosed herein are nucleic acid molecules comprising one or more nucleic acid sequences that encode synthetic consensus Survivin antigens. Vectors, compositions, and vaccines comprising one or more nucleic acid sequences that encode synthetic consensus Survivin antigens are disclosed. Methods of treating a subject with a Survivin-expressing tumor and methods of preventing a Survivin-expressing tumor are disclosed. Synthetic consensus Survivin antigens are disclosed.
    Type: Grant
    Filed: December 13, 2018
    Date of Patent: August 20, 2024
    Assignee: Inovio Pharmaceuticals, Inc.
    Inventors: Jian Yan, Anna Slager, Bradley Garman, Neil Cooch
  • Patent number: 12059459
    Abstract: The present invention relates to an anticancer vaccine which includes polynucleotides or polypeptides, methods of treatment of cancer wherein such an anticancer vaccine is used as well as methods for producing the vaccine. The vaccine includes a polynucleotide with a nucleotide sequence encoding a targeting unit, a dimerization unit, a first linker and an antigenic unit. The antigenic unit includes from 3 to 50 antigenic subunits separated by a second linker with each antigenic subunit having at least a part of a cancer neoepitope sequence. The vaccine can include a polypeptide encoded by the polynucleotide or a dimeric protein with two polypeptides encoded by the polynucleotide.
    Type: Grant
    Filed: December 21, 2021
    Date of Patent: August 13, 2024
    Assignee: Nykode Therapeutics ASA
    Inventors: Stine Granum, Elisabeth Stubsrud, Agnete Brunsvik Fredriksen
  • Patent number: 12055541
    Abstract: The present disclosure provides a system comprising a communication interface and computer for assigning a label to the biomolecule fingerprint, wherein the label corresponds to a biological state. The present disclosure also provides a sensor arrays for detecting biomolecules and methods of use. In some embodiments, the sensor arrays are capable of determining a disease state in a subject.
    Type: Grant
    Filed: September 1, 2023
    Date of Patent: August 6, 2024
    Assignee: THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
    Inventors: Omid Farokhzad, Morteza Mahmoudi, Claudia Corbo
  • Patent number: 12050218
    Abstract: The use of mitochondrial protease OMA1 as a theranostic marker for breast cancer, tumor progression, metastatis and drug responsiveness is disclosed herein.
    Type: Grant
    Filed: January 12, 2018
    Date of Patent: July 30, 2024
    Assignee: NUtech Ventures
    Inventors: Srivatsan Kidambi, Oleh Khalimonchuk
  • Patent number: 12025615
    Abstract: Provided herein are methods for classifying how a subject having a cancer will respond to immunotherapeutic (IT) therapy based on the subject's immunosignature or frameshift signature. Also provided herein are methods for classifying a subject having a cancer as having a good prognosis or a poor prognosis based on the subject's immunosignature or frameshift signature.
    Type: Grant
    Filed: September 13, 2018
    Date of Patent: July 2, 2024
    Assignee: Arizona Board of Regents on behalf of Arizona State University
    Inventor: Stephen Johnston